-
Janus Kinases Jaks Inhibitor Drug Report 2025 – For Strategy Officers And Market Intelligence Teams
30 Jun 2025 11:46 GMT
… increasing treatment accessibility … Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Galapagos NV, Theravance … drug after demonstrating its safety and efficacy for specific medical … and Drug Administration FDA …
-
Theravance Biopharma announces Viatris receives China NMPA approval for Yupelri inhalation solution to treat COPD
27 Jun 2025 11:40 GMT
… granted an Orphan Drug Designation for ampreloxetine for the treatment of symptomatic … time).
Theravance Biopharma, Inc.'s focus is to deliver Medicines that … of FDA-approved Yupelri (revefenacin) inhalation solution indicated for the maintenance treatment …
-
Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China
26 Jun 2025 23:33 GMT
… from China's National Medical Products Administration for YUPELRI inhalation … muscarinic antagonist approved for maintenance treatment of chronic obstructive pulmonary disease … received in third quarter, 2025. Theravance Biopharma is also eligible for …
-
How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
24 Jun 2025 12:20 GMT
… is high for a biotech bringing new drugs to the market. But … co-founder of Theravance, a company that brought five medications to market … in phase 1/2 trials inhibits the protein beta-catenin … 90s when we were funding Theravance with an A round of …
-
Antibiotic Collaboration and Licensing Agreements Analysis Report 2025: Explore 137 Deals with In-Depth Analysis and Access to Actual Contract Documents - ResearchAndMarkets.com
20 Jun 2025 13:41 GMT
… Directory of antibiotic deal records covering pharmaceutical and biotechnology
The leading antibiotic deals … Pharmaceutical
Taiba
TaiGen Biotechnology
TB Alliance
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance …
-
Sanofi pays out two STAT6 milestones; Theravance sells more Trelegy royalties
02 Jun 2025 17:49 GMT
-
Theravance Biopharma To Sell Remaining Interest In Trelegy Ellipta To GSK For $225 Mln, Stock Up
03 Jun 2025 01:23 GMT
Theravance Biopharma, Inc. (TBPH), Monday announced … obstructive pulmonary disease or asthma treatment, to GSK (GSK) for $225 …
-
Theravance hands off the last of its Trelegy royalties to GSK for $225M
02 Jun 2025 17:13 GMT
… royalties for sales of the drug from and after 2029 outside … evaluated in a phase 3 trial.
Theravance is still rebuilding after major … a series of three failed trials left it to cut 75% …
-
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease
30 May 2025 18:06 GMT
… Lycera, Samsung Bioepis, Theravance. S Danese has … AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, … ’s disease: medical treatment. J Crohns … drugs for inflammatory bowel disease treatment-insights from phase II and III trials …
-
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
09 May 2025 16:59 GMT
… an investigational medicine for the treatment of symptomatic … -blind, randomized withdrawal trial, designed to demonstrate … please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the … endpoints for clinical trials. These statements are …
About
© 1995-2025